Israel Englander Apellis Pharmaceuticals, Inc. Put Options Transaction History

Millennium Management LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$28.84 - $41.15 $124,012 - $176,945	-4,300 Reduced 35.54%	7,800 $224,000
Q2 2024 Aug 14, 2024	SELL	$38.07 - $59.71 $2.19 Million - $3.43 Million	-57,400 Reduced 82.59%	12,100 $464,000
Q1 2024 May 15, 2024	BUY	$55.39 - $72.47 $2.58 Million - $3.38 Million	46,600 Added 203.49%	69,500 $4.09 Million
Q4 2023 Feb 14, 2024	SELL	$37.14 - $64.82 $48,282 - $84,265	-1,300 Reduced 5.37%	22,900 $1.37 Million
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $1.86 Million - $2.26 Million	24,200 New	24,200 $2.2 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $3.58 Million - $5.57 Million	80,000 New	80,000 $5.46 Million

302

113M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.13B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.